Survivin as a therapeutic target for neuroendocrine neoplasms.
Hane Y, Tsuchikawa T, Nakamura T, Hatanaka KC, Sasaki K, Kawai N, Takeuchi S, Tanaka K, Nakanishi Y, Asano T, Noji T, Shichinohe T, Hatanaka Y, Hirohshi Y, Torigoe T, Hirano S.
Hane Y, et al. Among authors: nakamura t.
Neuroendocrinology. 2025 Jan 2:1-31. doi: 10.1159/000543270. Online ahead of print.
Neuroendocrinology. 2025.
PMID: 39746333